Abivax: Downgrading To 'Hold' As NDA Obefazimod Still Underway Despite Major Safety Risks
2026-06-02 13:33:24 ET
The last time I spoke about Abivax (ABVX), it was with respect to a Seeking Alpha article entitled " Abivax: Maintaining 'Strong Buy' on Buyout Speculation And Obefazimod Advancement ." With respect to this article, I mentioned that the company was working on the evaluation of its first-in-class miR-124 enhancer obefazimod for the treatment of adults with moderate-to-severe ulcerative colitis [UC] in the ongoing phase 3 ABTECT study. Plus, it was expected to release 44-week maintenance data from this trial. I had a "Strong Buy" rating in the previous article, and today I'm going to downgrade it to a "Hold" rating. The reason why is because it did achieve unprecedented clinical remission data using obefazimod to treat these patients with UC. Both the 25 mg and 50 mg doses of this drug achieved the primary endpoint and met all key secondary endpoints at week 44....
Read the full article on Seeking Alpha
For further details see:
Abivax: Downgrading To 'Hold' As NDA Obefazimod Still Underway Despite Major Safety Risks
NASDAQ: ABVX
ABVX Trading
3.27% G/L:
$99.835 Last:
1,550,008 Volume:
$105.18 Open:
